PuSH - Publication Server of Helmholtz Zentrum München: Antigen-armed antibodies targeting B lymphoma cells effectively activate antigen-specific CD4<sup>+</sup> T cells.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Yu, X.* ; Ilecka, M.* ; Bartlett, E.J.* ; Schneidt, V.* ; Bhat, R.* ; Mautner, J. ; Feederle, R. ; Delecluse, H.J.*

Antigen-armed antibodies targeting B lymphoma cells effectively activate antigen-specific CD4⁺ T cells.

Blood 125, 1601-1610 (2015)

Publ. Version/Full Text

DOI

PMC

	Closed

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

The treatment of non-Hodgkin lymphomas has benefited enormously from the introduction of monoclonal antibody-based therapies. However, the efficacy of these treatments varies with lymphoma subtypes and typically decreases with subsequent relapses. Here, we report on antigen-armed antibodies (AgAbs) as a potential treatment for B-cell lymphoma. AgAbs include antigens from ubiquitous pathogens, such as Epstein-Barr virus (EBV), that persist in their host and elicit strong lifelong T cell responses. They act as vectors by introducing antigen directly into tumor cells to induce an antigen-specific CD4+ T cell response against these cells. We have fused antibodies targeting human B-cell surface receptors (CD19-22) to immunodominant T cell antigens from EBV proteins, including EBNA1, EBNA3B and EBNA3C. Exposure of EBV-transformed B-cells and of BL cells to AgAbs led to antigen presentation, T cell recognition and target cell killing. The efficiency of AgAb action paralleled the abundance of the targeted molecules on lymphoma cells as well as their HLA class II expression levels. AgAbs can also induce the activation and proliferation of EBV-specific memory CD4+ T cells ex vivo. These studies show the potential of AgAbs as an effective therapeutic strategy against B-cell lymphomas.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

10.452

2.677

PuSH - Publication Server of Helmholtz Zentrum München

Antigen-armed antibodies targeting B lymphoma cells effectively activate antigen-specific CD4+ T cells.

Antigen-armed antibodies targeting B lymphoma cells effectively activate antigen-specific CD4⁺ T cells.